TMCI TREACE MEDICAL CONCEPTS, INC.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1630627 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-7.1%
TTM net income YoY-11.3%
TTM EPS YoY-6.2%
Revenue 3-yr CAGR5.2%
Net income 3-yr CAGR—
Margins
Gross margin79.6%
Operating margin-24.4%
Net margin-27.4%
FCF margin-9.1%
EBITDA margin-21.1%
Returns
ROE-74.0%
ROA-29.7%
ROIC (approx.)-31.2%
Asset turnover1.08x
Leverage & solvency
Liabilities / assets65.6%
Debt / equity0.97x
Current ratio2.58x
Interest coverage-8.17x
Cash quality & payout
Operating cash flow / net income0.16x
Accruals ratio-25.0%
Payout ratio—
Capex / revenue4.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $48.25M | $45.38M | $47.20M | $62.52M | $50.21M | $47.39M | $52.57M | $68.71M |
| Cost of revenue | $9.90M | $9.77M | $9.79M | $12.12M | $10.51M | $9.63M | $10.68M | $13.23M |
| Gross profit | $38.35M | $35.61M | $37.41M | $50.40M | $39.71M | $37.75M | $41.89M | $55.48M |
| R&D expense | $4.49M | $4.38M | $4.62M | $4.54M | $4.68M | $5.50M | $5.56M | $5.21M |
| SG&A expense | $15.68M | $15.25M | $16.18M | $14.53M | $16.28M | $16.14M | $15.79M | $13.61M |
| Operating income | -$11.53M | -$14.96M | -$17.17M | -$5.92M | -$15.68M | -$16.97M | -$15.58M | -$204,000 |
| Interest expense | $1.58M | $1.56M | $1.57M | $1.35M | $1.34M | $1.32M | $1.31M | $1.31M |
| Net income | -$12.57M | -$15.87M | -$17.96M | -$9.39M | -$16.29M | -$17.40M | -$15.92M | -$501,000 |
| EBITDA | -$10.03M | -$13.46M | -$16.27M | -$3.11M | -$13.18M | -$14.67M | -$13.12M | $2.03M |
| EPS (basic) | -0.19 | -0.24 | -0.28 | — | -0.26 | -0.28 | -0.25 | — |
| EPS (diluted) | -0.19 | -0.24 | -0.28 | — | -0.26 | -0.28 | -0.25 | — |
| Weighted avg. shares (diluted) | 65.46M | 65.05M | 64.59M | — | 63.52M | 63.01M | 62.66M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $7.76M | $12.61M | $9.54M | $10.71M | $7.69M | $8.05M | $13.37M | $11.35M |
| Short-term investments | $32.04M | $33.01M | $42.31M | $37.66M | $49.73M | $61.24M | $62.72M | $64.33M |
| Receivables | $30.22M | $28.73M | $30.36M | $42.16M | $32.96M | $30.33M | $31.11M | $40.80M |
| Inventory | $42.30M | $39.54M | $36.37M | $36.03M | $41.42M | $42.40M | $37.94M | $39.26M |
| Current assets | $118.69M | $120.45M | $123.47M | $132.05M | $138.00M | $147.60M | $149.44M | $161.40M |
| PP&E, net | $33.04M | $32.50M | $32.06M | $29.75M | $29.97M | $29.71M | $27.13M | $25.95M |
| Goodwill | $12.81M | $12.81M | $12.81M | $12.81M | $12.81M | $12.81M | $12.81M | $12.81M |
| Intangibles | $6.41M | $6.65M | $6.89M | $7.12M | $7.36M | $7.60M | $7.84M | $8.07M |
| Total assets | $179.30M | $181.06M | $184.10M | $190.58M | $196.59M | $206.44M | $205.85M | $217.09M |
| Current liabilities | $46.08M | $41.50M | $34.49M | $30.64M | $40.91M | $41.90M | $33.18M | $34.92M |
| Short-term debt | $3.78M | $3.17M | $1.78M | $1.75M | $1.80M | $1.11M | $45,000 | $0 |
| Long-term debt | $56.26M | $56.04M | $55.82M | $55.58M | $53.53M | $53.45M | $53.38M | $53.31M |
| Total debt | $60.05M | $59.21M | $57.60M | $57.33M | $55.33M | $54.57M | $53.42M | $53.31M |
| Total liabilities | $117.65M | $113.32M | $106.91M | $103.25M | $107.40M | $108.83M | $100.50M | $104.20M |
| Shareholders' equity | $61.65M | $67.74M | $77.19M | $87.33M | $89.19M | $97.61M | $105.34M | $112.89M |
| Net debt | $52.28M | $46.60M | $48.05M | $46.62M | $47.64M | $46.52M | $40.05M | $41.96M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.25M | -$4.70M | $7.24M | -$8.03M | -$9.09M | -$3.05M | $4.20M | -$4.21M |
| Capital expenditure | $2.17M | $2.20M | $3.06M | $2.40M | $2.81M | $4.77M | $3.54M | $3.07M |
| Free cash flow | -$5.43M | -$6.90M | $4.18M | -$10.42M | -$11.90M | -$7.82M | $655,000 | -$7.28M |
| Investing cash flow | -$1.26M | $7.07M | -$7.82M | $9.67M | $8.74M | -$3.26M | -$1.89M | $3.42M |
| Financing cash flow | -$335,000 | $696,000 | -$588,000 | $1.38M | -$10,000 | $987,000 | -$282,000 | $26,000 |
| Depreciation & amortization | $1.50M | $1.50M | $899,000 | $2.81M | $2.50M | $2.30M | $2.46M | $2.24M |
| Stock-based compensation | $6.93M | $6.46M | $8.03M | $7.55M | $8.00M | $9.58M | $8.69M | $8.55M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.